Home Logon FTA Investment Managers Blog Subscribe About Us Contact Us

Search by Ticker, Keyword or CUSIP       
 
 

Biotechnology, 57  Ticker: FKJWXX
 
Description
A unit investment trust that seeks to provide above-average capital appreciation by investing in a concentrated portfolio of biotechnology related companies.
Please note that there is no assurance the objective will be met.
 
Summary
Product Code: BTGR57
Portfolio Status: Secondary
Initial Offer Date: 05/09/2022
Secondary Date: 08/05/2022
Portfolio Ending Date: 05/09/2024
Tax Structure: Regulated Investment Company
Distributions: Semi-Annual
 
Initial Offer Price: $10.0000
NAV(*): $10.0657
POP(*): Not Avail
Remaining Deferred Sales Charge: $0.0000
* As of Trade Date: 03/28/2024 4:00pm ET
The Public Offering Price (POP) represents the net asset value per unit plus any applicable organization costs and sales charges. The Net Asset Value (NAV) represents the value per unit of a trust’s portfolio securities and other assets reduced by applicable deferred sales charges and other liabilities.

 Historical 12-Month Distribution of Trust Holdings:^
Rate  Per Unit (as of 3/28/2024)
----- $0.03460
^ There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The historical 12-month distribution per unit of the securities included in the trust are for illustrative purposes only and are not indicative of the trust's distribution or distribution rate. The historical 12-month distribution per unit is based on the weighted average of the trailing twelve month distributions paid by the securities included in the portfolio. The historical 12-month distributions are reduced to account for the effects of fees and expenses, which will be incurred when investing in a trust. For trusts that include funds, distributions may include realized short term capital gains, realized long-term capital gains and/or return of capital. Certain of the issuers may have reduced their dividends or distributions over the prior twelve months. The distribution per unit paid by the trust may be higher or lower than the amount shown above due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, or the sale of securities in the portfolio.

 Holdings Analysis Click here to Perform a Benchmark Comparison  
 Sector Weighting
Communication Services  Communication Services 0.00%
Consumer Discretionary  Consumer Discretionary 0.00%
Consumer Staples  Consumer Staples 0.00%
Energy  Energy 0.00%
Financials  Financials 0.00%
Health Care  Health Care 99.83%
Industrials  Industrials 0.00%
Information Technology  Information Technology 0.00%
Materials  Materials 0.00%
Real Estate  Real Estate 0.00%
Utilities  Utilities 0.00%
Other  Other 0.17%
 
  Large Mid Small  
Growth  21.09% 23.41% 1.08%  
Value  27.17% 27.08% 0.00%  

 Style Weighting
Large-Cap Growth 21.09%
Large-Cap Value 27.17%
Mid-Cap Growth 23.41%
Mid-Cap Value 27.08%
Small-Cap Growth 1.08%
Small-Cap Value 0.00%
Undetermined 0.17%
 Composition
U.S. Stocks 89.12%   Other 0.17%
Non-U.S. Stocks 10.71%      
The style and sector characteristics of the portfolio are determined as of 03/28/2024 and will likely vary thereafter due to market fluctuations in the underlying securities.  

 Key Stats
Weighted Average Market Cap $66,119
Price/Earnings 29.23
Price/Book 3.93
As of 3/28/2024
All market capitalization numbers are in USD$ Millions. All figures are subject to change.

 Holdings  Export Current Holdings | View Initial Holdings  
NameSymbolSectorStyleWeighting
 Neurocrine Biosciences, Inc. NBIX Health Care  Health Care Mid-Cap Growth 7.05%
 Vertex Pharmaceuticals Incorporated VRTX Health Care  Health Care Large-Cap Growth 6.55%
 Regeneron Pharmaceuticals, Inc. REGN Health Care  Health Care Large-Cap Value 6.35%
 United Therapeutics Corporation UTHR Health Care  Health Care Mid-Cap Value 5.12%
 Amgen Inc. AMGN Health Care  Health Care Large-Cap Growth 4.93%
 Gilead Sciences, Inc. GILD Health Care  Health Care Large-Cap Value 4.83%
 AbbVie Inc. ABBV Health Care  Health Care Large-Cap Growth 4.81%
 IQVIA Holdings Inc. IQV Health Care  Health Care Large-Cap Growth 4.80%
 Repligen Corporation RGEN Health Care  Health Care Mid-Cap Growth 4.70%
 BioMarin Pharmaceutical Inc. BMRN Health Care  Health Care Mid-Cap Value 4.47%
 Exelixis, Inc. EXEL Health Care  Health Care Mid-Cap Value 4.46%
 Biogen Inc. BIIB Health Care  Health Care Large-Cap Value 4.45%
 Alnylam Pharmaceuticals, Inc. ALNY Health Care  Health Care Mid-Cap Growth 4.44%
 Thermo Fisher Scientific Inc. TMO Health Care  Health Care Large-Cap Value 4.32%
 Halozyme Therapeutics, Inc. HALO Health Care  Health Care Mid-Cap Growth 4.20%
 CSL Limited (ADR) CSLLY Health Care  Health Care Large-Cap Value 4.05%
 Genmab A/S (ADR) GMAB Health Care  Health Care Mid-Cap Value 3.92%
 Avantor, Inc. AVTR Health Care  Health Care Mid-Cap Value 3.31%
 Moderna, Inc. MRNA Health Care  Health Care Large-Cap Value 3.17%
 Incyte Corporation INCY Health Care  Health Care Mid-Cap Value 3.06%
 Bio-Techne Corporation TECH Health Care  Health Care Mid-Cap Growth 3.02%
 BioNTech SE (ADR) BNTX Health Care  Health Care Mid-Cap Value 2.74%
 Maravai LifeSciences Holdings, Inc. (Class A) MRVI Health Care  Health Care Small-Cap Growth 1.08%
 
Total Number of Holdings:    23
Underlying Securities information represented above is as of 03/28/2024 but will vary with future fluctuations in the market.

Risk Considerations

Equity Risk. An investment in a portfolio containing common stocks is subject to certain risks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

Sector Concentration Risk. A portfolio which is concentrated in an individual sector is subject to additional risks, including limited diversification.

Biotechnology Risk. The companies engaged in the biotechnology and pharmaceutical industries are subject to fierce competition, substantial research and development costs, governmental regulations, pricing constraints, and their products and services may be subject to rapid obsolescence. Biotechnology and pharmaceutical stocks have experienced extreme price and volume fluctuations that are often unrelated to their operating performance. In addition, health crises, such as a pandemic outbreak, can severely impact the health care industry in particular.

Buy & Hold Risk – Taxable Trusts. This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

COVID-19 Economic Impact Risk. The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease.

Foreign Securities Risk. Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.

Large-Cap Risk. Large capitalization companies may grow at a slower rate than the overall market.

Market Disruption Risk. Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain investments as well as performance.

Pharmaceutical Risk. The companies engaged in the pharmaceutical sector are subject to fierce competition, substantial research and development costs, governmental regulations, pricing constraints, and their products and services may be subject to rapid obsolescence.

Small-Cap and Mid-Cap Risk. An investment in a portfolio containing small-cap and mid-cap companies is subject to additional risks, as the share prices of small-cap companies and certain mid-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.

Volatility Risk. The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

Operational Risk. As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.

The style and capitalization characteristics used to describe the stocks are designed to help you understand how they fit into your overall investment plan. Due to changes in the value of the stocks the characteristics may vary over time. In general, growth stocks have high relative price-to-book ratios while value stocks have low relative price-to-book ratios. In determining market capitalization characteristics, we analyze the market capitalizations of the 3,000 largest stocks in the U.S. (excluding foreign securities, ADRs, limited partnerships and regulated investment companies) on a monthly basis. Companies with market capitalizations among the largest 10% are considered Large-Cap securities, the next 20% are considered Mid-Cap securities and the remaining securities are considered Small-Cap securities.

You should carefully consider the trust's investment objectives, risks, and charges and expenses before investing. Contact your financial professional or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the trust. Read it carefully before you invest.

This product information does not constitute an offer to sell, or a solicitation of an offer to buy securities in any state to any person to whom it is not lawful to make such an offer. Sales of any of these securities must include prospectus delivery and the services of a retail broker/dealer duly licensed in the appropriate states.

Not FDIC Insured, Not Bank Guaranteed and May Lose Value.

CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by FactSet Research Systems Inc. and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, ©2024 CUSIP Global Services. "CUSIP" is a registered trademark of the American Bankers Association.

Fund Cusip Information
30326N202 (Cash)
30326N210 (Reinvest)
30326N228 (Cash-Fee)
30326N236 (Reinvest-Fee)
Printer Friendly Page Printer Friendly Page

 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
Follow First Trust:  
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2024 All rights reserved.